Titan Biotech Ratios

Titan Biotech Ltd Ratios

The Titan Biotech Ltd Ratios page provides a complete fundamental analysis of Titan Biotech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Titan Biotech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Titan Biotech Ltd (NSE: , BSE: 524717) is currently trading at ₹1212.15, with a market capitalization of ₹10.02B. As a major player in the Health technology sector and Biotechnology industry, Titan Biotech Ltd remains a key stock for fundamental analysis using Titan Biotech Ltd Ratios.

Titan Biotech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Titan Biotech Ltd P/E ratio currently stands at 16.18, making it one of the most tracked metrics in Titan Biotech Ltd Ratios.

Historically, the Titan Biotech Ltd P/E ratio has shown strong fluctuations:

• 2024: 16.18
• 2023: 17.56
• 2022: 6.55
• 2021: 9.99
• 2020: 5.05

The decline in Titan Biotech Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Titan Biotech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.27.

Historical P/B trend:

• 2024: 2.27
• 2023: 3.27
• 2022: 1.48
• 2021: 2.51

Titan Biotech Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Titan Biotech Ltd P/S ratio currently stands at 2.23, an important part of Titan Biotech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.23
• 2023: 2.66
• 2022: 1.13
• 2021: 1.75

A stable or declining Titan Biotech Ltd P/S ratio indicates cautious market sentiment.

Titan Biotech Ltd Price to Cash Flow Ratio (P/CF)

The Titan Biotech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 18.03.

Historical Titan Biotech Ltd Price to Cash Flow Ratio:

• 2024: 18.03
• 2023: 21.85
• 2022: 7.96
• 2021: 10.23
• 2020: 8.73

The declining Titan Biotech Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Titan Biotech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Titan Biotech Ltd EV currently stands at ₹3.46B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 3.46B
• 2023: 4.42B
• 2022: 1.66B
• 2021: 2.19B

Titan Biotech Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Titan Biotech Ltd EV/EBITDA ratio is currently 13.28, a key metric in Titan Biotech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 13.28
• 2023: 12.64
• 2022: 5.54
• 2021: 6.92

Higher Titan Biotech Ltd EV/EBITDA suggests premium valuation.

Titan Biotech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Titan Biotech Ltd D/E ratio is currently 0.02, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.02
• 2023: 0.06
• 2022: 0.08
• 2021: 0.10

Titan Biotech Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Titan Biotech Ltd ROE currently stands at 15.01%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 15.01
• 2023: 20.42
• 2022: 23.82
• 2021: 27.98

Titan Biotech Ltd maintains stable profitability levels.

Titan Biotech Ltd Ratios Analysis Summary

The Titan Biotech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Titan Biotech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Titan Biotech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.